OncoMatch/Clinical Trials/NCT06593522
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Is NCT06593522 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies AMG 193 for mtap-deleted nsclc.
Treatment: AMG 193 — The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
MTAP-deleted (Homozygous deletion of MTAP) NSCLC
Excluded: EGFR mutation
Tumors harboring the following mutations amenable to targeted therapies: epidermal growth factor receptor (EGFR)
Excluded: ALK fusion
Tumors harboring the following mutations amenable to targeted therapies: ALK receptor tyrosine kinase (ALK)
Excluded: ROS1 fusion
Tumors harboring the following mutations amenable to targeted therapies: ROS proto-oncogene 1 (ROS1)
Excluded: NTRK1 fusion
Tumors harboring the following mutations amenable to targeted therapies: neurotrophic tyrosine receptor kinase (NTRK)
Excluded: NTRK2 fusion
Tumors harboring the following mutations amenable to targeted therapies: neurotrophic tyrosine receptor kinase (NTRK)
Excluded: NTRK3 fusion
Tumors harboring the following mutations amenable to targeted therapies: neurotrophic tyrosine receptor kinase (NTRK)
Excluded: MET mutation
Tumors harboring the following mutations amenable to targeted therapies: MET proto-oncogene (MET)
Excluded: BRAF mutation
Tumors harboring the following mutations amenable to targeted therapies: B-Raf proto-oncogene (BRAF)
Excluded: RET fusion
Tumors harboring the following mutations amenable to targeted therapies: RET proto-oncogene (RET)
Excluded: HER2 (ERBB2) mutation
Tumors harboring the following mutations amenable to targeted therapies: Human epidermal growth factor receptor 2 (HER2/ERBB2)
Excluded: KRAS G12C
Tumors harboring the following mutations amenable to targeted therapies: KRAS proto-oncogene G12C (KRAS G12C)
Prior therapy
Must have received: systemic therapy — locally advanced and unresectable or metastatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Duarte, California
- Cedars-Sinai Medical Center · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
- University of California Los Angeles · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify